Novartis India Limited
NSE: NOVARTIND · Pharmaceuticals · sector
₹1,790.20NSE close 2026-10-26
Key numbers
Market cap₹4,418 cr
Price₹1,790.20
52w high / low₹2,589 / ₹950
P/E45.2xSector median 27.9x
P/B5.4xSector median 2.9x
Book value₹331.4
Dividend yield1.39%Sector median 0.48%
ROE12.2%Sector median 11.7%
ROCE16.7%Sector median 12.3%
OPM27.5%Sector median 14.0%
Debt / equity0.00xSector median 0.16x
EV/EBITDA36.9xSector median 18.6x
Interest cover112.2x
Current ratio5.30x
Sales growth 3y-2.2%Sector median +9.6%
Profit growth 3y-3.4%Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹668 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 112.2x in the last 12 months.
- Other income was 38% of net profit in the last 12 months.
- Dividend paid in 3 of the last 5 financial years.
- Price ₹1,790.20 on 2026-10-26: -30.8% from the 52-week high, +88.4% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹2,186.40 · low ₹748.95
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 84 | 88 | 90 | 86 | 91 | 104 |
| EBITDA | 24 | 27 | 24 | 22 | 21 | 35 |
| OPM % | 28.5% | 31.1% | 26.4% | 26.0% | 22.8% | 33.6% |
| Other income | 11 | 11 | 9 | 9 | 10 | 9 |
| Net profit | 29 | 28 | 24 | 16 | 25 | 32 |
| EPS (₹) | 11.87 | 11.19 | 9.81 | 6.52 | 10.23 | 13.05 |
| Revenue YoY | +8.0% | +18.6% | ||||
| Profit YoY | -13.8% | +16.6% |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 400 | 379 | 335 | 356 | 354 | 371 |
| EBITDA | -23 | 65 | 65 | 91 | 94 | 102 |
| Net profit | -4 | 103 | 85 | 101 | 93 | 98 |
| EPS (₹) | -1.51 | 41.86 | 34.50 | 40.87 | 37.74 | 39.61 |
| Revenue growth | -5.3% | -11.5% | +6.3% | -0.5% | – | |
| Profit growth | – | -17.6% | +18.4% | -7.7% | – | |
| Dividend / share (₹) | 10.00 | 10.00 | 10.00 | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | -2.2% | – | – |
| Net profit | -3.4% | – | – |
| EPS | -3.4% | – | – |
| Share price | – | – (2y) | – |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 785 | 818 |
| Borrowings | 0 | 0 |
| Cash & equivalents | 648 | 668 |
| Total assets | 948 | 978 |
| Fixed assets | 5 | 3 |
| Capital work in progress | 0 | – |
| Investments | 0 | 0 |
| Receivables | 40 | 37 |
| Inventory | 41 | 53 |
| Payables | 51 | 55 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 75 | 47 |
| Cash from investing | -3 | 18 |
| Cash from financing | -64 | -64 |
| Capex | 0 | 0 |
| Free cash flow | 75 | 46 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 12.9% | 11.4% |
| ROCE % | 16.7% | 16.0% |
| Debtor days | 41 | 38 |
| Inventory days | 74 | 98 |
| Payable days | 93 | 101 |
| Cash conversion cycle (days) | 22 | 35 |
| Working capital days | 619 | 642 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| NOVARTIND | ₹4,418 cr | 45.2x | 5.4x | 12.2% | 16.7% | 27.5% | -2.2% | 1.39% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2023-07-20 | Dividend | Annual General Meeting/Dividend - Rs 10 Per Share/Special Dividend - Rs 37.50 Per Share |
| 2022-07-20 | Dividend | Dividend - Rs 10 Per Share |
| 2021-08-17 | Dividend | Dividend - Rs 10 Per Share |
| 2002-07-02 | Dividend | Dividend-150% |
| 2001-10-08 | Dividend | Dividend-150% |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | NOVARTIND |
| BSE code | 500672 |
| ISIN | INE234A01025 |
| Face value | ₹5.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-22 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = NSE close 2026-10-26.